LUTS

Laborie Unveils Positive Study Results for Optilume® BPH Catheter System

Retrieved on: 
월요일, 5월 13, 2024
Funding of science, CE, Principal, Patient, AUA, FDA, LUTS, Maxima and minima, PINNACLE, FACS, CFIA, IPSS, MIST, Paclitaxel, BPH, Mount Sinai Health System, International Prostate Symptom Score, Medical device

PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.

Key Points: 
  • PORTSMOUTH, N.H., May 13, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.
  • The Optilume® BPH Catheter System is a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for treating lower urinary tract symptoms (LUTS) secondary to BPH.
  • Dr. Kaplan, Director of the Men's Wellness Program at Mount Sinai Health System and Principal investigator for the Optilume® BPH Catheter System PINNACLE trial, presented 2-year data from the PINNACLE study and 5-year data from the EVEREST study.
  • "Optilume for BPH is an exciting therapy that offers a safe, effective, and minimally invasive procedure for men suffering from BPH," remarked Dr. Kaplan, "The long-term results from both trials show positive outcomes for men suffering from BPH who undergo this minimally invasive procedure."

Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH

Retrieved on: 
화요일, 5월 7, 2024
IMPACT, FDA, Teleflex, Urology, Prostate, PVP, PUL, LUTS, Heat, TFX, MD, TURP, Research, Mars, Prostatic urethral lift, Patient, Physician, Medicine, Urethra, AUA, ATC, Database, Patient satisfaction, Quality of life, BPH

“For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.

Key Points: 
  • “For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.
  • ***5
    Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe postoperative complications on a per case basis from 2019 to 2022 in the MAUDE database.
  • The goal is for the provider and patient to decide whether to continue, stop, or switch to another therapy based on the symptomatic response of medication.
  • **9 It is the only leading enlarged prostate procedure that does not require heating, cutting, or destruction of prostate tissue.10-11
    For more information about the UroLift™ System, visit www.UroLift.com .

Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia

Retrieved on: 
월요일, 5월 6, 2024
FDA, Bleeding, Safety, Risk, American Urological Association, Abstract, LUTS, ASC, Surgeon, TURP, International Prostate Symptom Score, Patient, SDD, AUA, Health, Patient satisfaction, Clinical trial, SAN, BPH, IPSS, Benign prostatic hyperplasia

The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.
  • “The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign prostatic hyperplasia, regardless of prostate size or shape," said Reza Zadno, CEO of PROCEPT BioRobotics.
  • Three surgeons at Potomac Urology collected data on 812 consecutive men treated with Aquablation therapy.
  • We have treated more than 800 men with Aquablation therapy and feel that the results truly speak for themselves,” said Shawn Marhamati, MD, MS, at Potomac Urology.

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

Retrieved on: 
화요일, 4월 23, 2024
Urology, Safety, American Urological Association, Abstract, ASC, LUTS, Surgeon, TURP, Patient, AMVETS, SDD, AUA, Robotics, Biorobotics, Health, USAV, Clinical trial, SAN, BPH

PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.

Key Points: 
  • PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.
  • “The growing body of real-world clinical evidence on Aquablation therapy is reflected by the extensive range of presentations being showcased at the AUA,” said Reza Zadno, CEO of PROCEPT BioRobotics.
  • The continued momentum and interest in Aquablation therapy are a testament to our unwavering commitment to advancing innovative, safe and effective treatment options for patients.”
    Registered attendees can access the full list of Aquablation therapy presentations here.
  • PROCEPT BioRobotics will sponsor additional satellite events during AUA at both the Henry B. Gonzalez Convention Center and off-site, including:

Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

Retrieved on: 
금요일, 3월 29, 2024
Urology, Disease, Education, Patient, LUTS, Malignancy, BPH, FDA, Pharmaceutical industry

PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.

Key Points: 
  • PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.
    CarePath's simplistic model allows the device to be shipped directly to the patient's home and uses embedded cellular connectivity.
  • With CarePath, 91% of patients returned to the clinic to review the CarePath Uroflow report with their provider and consider surgical intervention.
  • "The team at iO Urology developed a state-of-the-art device with a dynamic patient ecosystem that empowers patient engagement as a superior standard of care.
  • "We're eager to collaborate with Laborie, pioneers in diagnostic and therapeutic urologic healthcare," said iO Urology Co-Founder and CEO Britton Garrett.

2024 AUA Data Research Program Awardees Announced

Retrieved on: 
화요일, 2월 13, 2024
FACS, Patient, Census, Overactive bladder, MBA, Master of Philosophy, Registry, LUTS, Urology, Practice, Abstract, AUA, AQUA, Integration, Health policy, United, American Urological Association, Workforce, Publication, Research

BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to select six research teams as recipients of the 2024 AUA Data Research Program.

Key Points: 
  • BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to select six research teams as recipients of the 2024 AUA Data Research Program.
  • The AUA Data Research Program (formerly AUA Data Grants), launched in May 2023, supports two clinical and four workforce research projects annually using data from AUA Data Repositories to address key knowledge gaps and emerging research questions related to urological care, workforce development, and health policy.
  • Awardees will use real-world clinical data from the AUA Quality (AQUA) Registry and population representative AUA Annual Census data to conduct clinical and workforce studies.
  • “In conceptualizing the AUA Data Research Program, we realize that there are many AUA members with outstanding research ideas but who may lack the resources to pursue these critical questions,” said Dr. Hung-Jui (Ray) Tan, Chair of the AUA Data Research Program.

American Urological Association Names New Research Chair

Retrieved on: 
목요일, 1월 11, 2024
Male, American Urological Association, Weill Cornell Medicine, Interstitial cystitis, MD, CPP, LUTS, Baylor College of Medicine, Baylor University, Chair, Signs and symptoms, NIH, AUA, Bangladesh Technical Education Board, The, Anesthesiology, Education, Management

BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.

Key Points: 
  • BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.
  • As Research Chair, Dr. Lai will lead the research components of the AUA and Urology Care Foundation missions, focusing on implementing strategic goals.
  • The main objective is to advance research in urologic diseases by engaging with the AUA Research Council and collaborating closely with the AUA Director of Research.
  • Specifically, the Chair partners with the AUA Office of Research and urologic research stakeholders to ensure the future of urology surgeon-scientists, enhance strategic programming in research funding and education, and support AUA research advocacy in public and private sectors.

Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization

Retrieved on: 
목요일, 11월 30, 2023
Medical Devices, Health, AMS, Acquisition, IP, Boston Scientific, Medtronic, Urology, Cleveland Clinic, Male, FDA, Uro, LUTS, Test management, Female, Axon Enterprise, Medical device, Compaq Contura

The Series A funding round includes investment from Laborie and other existing investors in the Company.

Key Points: 
  • The Series A funding round includes investment from Laborie and other existing investors in the Company.
  • Funding will be used to achieve FDA 510(k) clearance of the Glean™ Urodynamics System (Glean) and launch the product in the U.S. in 2024.
  • “Laborie looks forward to leveraging our expertise and leadership in the global urology market to support the Bright Uro team,” said Michael Frazzette, President & CEO of Laborie.
  • Bright Uro Founder and CEO Derek Herrera stated, “I am so proud of our team for achieving this incredible milestone!

Laborie Medical Technologies Invests in Medical Technology Start-Up Bright Uro

Retrieved on: 
목요일, 11월 30, 2023
Incontinence, Urine, Woman, Pressure, Lower urinary tract symptoms, Investor AB, Patient, System, Urethra, LUTS, Urinary incontinence, Standard of care, Test management, Urodynamic testing, Management, Urology, Gleaning

PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Key Points: 
  • PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.
  • Founded in 2021, Bright Uro is developing the Glean Urodynamic System™, a wireless, catheter-free, urodynamic monitoring system intended to quantify the pressure characteristics of the lower urinary tract.
  • "We're thrilled to be working with Laborie," says Bright Uro Founder & CEO Derek Herrera.
  • "Laborie looks forward to leveraging our expertise and leadership in the global urodynamics market to support the Bright Uro team," said Michael Frazzette, President & CEO of Laborie Medical Technologies.

Olympus Announces Two New Category I CPT Codes for the iTind Procedure

Retrieved on: 
금요일, 10월 20, 2023
Patient, Ageing, Olympus Corporation, Health care, Medicare, American Medical Association, Physician, LUTS, AMA, Urine, Blood, Urinary tract infection, CPT, Olympus, BPH, UNITE, Centers for Medicare & Medicaid Services, CMS, Health insurance, Medicaid

The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.

Key Points: 
  • The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.
  • CPT codes are granted and maintained by the AMA CPT Editorial Panel and are used by government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement.
  • The two new CPT codes for the iTind procedure will go into effect on or after January 1, 2025.
  • Patients who are candidates for the iTind procedure may be assisted in navigating medical insurance systems through the Olympus UNITE program.